184 related articles for article (PubMed ID: 35146578)
1. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.
Jiang C; Li A; Teng Y; Huang X; Ding C; Chen J; Xu J; Zhou Z
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2902-2916. PubMed ID: 35146578
[TBL] [Abstract][Full Text] [Related]
2. Radiomics signature from [
Jiang C; Huang X; Li A; Teng Y; Ding C; Chen J; Xu J; Zhou Z
Eur Radiol; 2022 Aug; 32(8):5730-5741. PubMed ID: 35298676
[TBL] [Abstract][Full Text] [Related]
3. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
4. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an
Wang H; Zhao S; Li L; Tian R
Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
[TBL] [Abstract][Full Text] [Related]
6. Baseline
Jing F; Liu Y; Zhao X; Wang N; Dai M; Chen X; Zhang Z; Zhang J; Wang J; Wang Y
EJNMMI Res; 2023 Oct; 13(1):92. PubMed ID: 37884763
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a [
Li M; Yao H; Zhang P; Zhang L; Liu W; Jiang Z; Li W; Zhao S; Wang K
Eur Radiol; 2023 May; 33(5):3354-3365. PubMed ID: 36547676
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
9. Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study.
Jiang C; Qian C; Jiang Z; Teng Y; Lai R; Sun Y; Ni X; Ding C; Xu Y; Tian R
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3949-3960. PubMed ID: 37606859
[TBL] [Abstract][Full Text] [Related]
10. Stacking Ensemble Learning-Based [
Zhao S; Wang J; Jin C; Zhang X; Xue C; Zhou R; Zhong Y; Liu Y; He X; Zhou Y; Xu C; Zhang L; Qian W; Zhang H; Zhang X; Tian M
J Nucl Med; 2023 Oct; 64(10):1603-1609. PubMed ID: 37500261
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of
Carlier T; Frécon G; Mateus D; Rizkallah M; Kraeber-Bodéré F; Kanoun S; Blanc-Durand P; Itti E; Le Gouill S; Casasnovas RO; Bodet-Milin C; Bailly C
J Nucl Med; 2024 Jan; 65(1):156-162. PubMed ID: 37945379
[TBL] [Abstract][Full Text] [Related]
12.
Cui Y; Jiang Y; Deng X; Long W; Liu B; Fan W; Li Y; Zhang X
Acad Radiol; 2023 Jul; 30(7):1408-1418. PubMed ID: 36437191
[TBL] [Abstract][Full Text] [Related]
13. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Overall Survival and Progression-Free Survival by the
Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
[No Abstract] [Full Text] [Related]
15. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
16. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
17. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
18. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
20. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
